Mostrando 10 resultados de: 16
Publisher
Basic and Clinical Pharmacology and Toxicology(2)
Journal of Pharmaceutical Health Services Research(2)
Drug Safety(1)
European Journal of Clinical Pharmacology(1)
Frontiers in Pharmacology(1)
Área temáticas
Medicina y salud(8)
Farmacología y terapéutica(7)
Problemas sociales y servicios a grupos(7)
Producción(4)
Enfermedades(3)
Origen
scopus(16)
Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study
ArticleAbstract: Background: In May 2020, the ACCESS (The vACCine covid-19 monitoring readinESS) project was launchedPalabras claves:Adverse events of special interest, Background rates, covid-19, Vaccine safetyAutores:Aragón M., Barbieri E., Bartolini C., Bryant V., Carlos E. Durán, Carreras J.J., de Burgos A., Diez-Domingo J., Dodd C., Ehrenstein V., Elbers R.J.H.J., García-Poza P., Giaquinto C., Gini R., Haug U., Huerta C., Kahlert J., Klungel O.H., Martín-Pérez M., Martínez-González M., Mira-Iglesias A., Pallejà-Millán M., Paoletti O., Schink T., Souverein P., Stona L., Sturkenboom M.C.J.M., Thurin N.H., Vergara-Hernández C., Villalobos F., Wang L., Weibel D., Willame C.Fuentes:scopusAnticholinergic Exposure in a Cohort of Adults Aged 80 years and Over: Associations of the MARANTE Scale with Mortality and Hospitalization
ArticleAbstract: Anticholinergics are frequently prescribed for older adults and can lead to adverse drug events. ThePalabras claves:Autores:Azermai M., Carlos E. Durán, Christiaens T., Dalleur O., Degryse J., Elseviers M., Klamer T., Vaes B., Vander Stichele R., Wauters M.Fuentes:scopusA Novel Scale Linking Potency and Dosage to Estimate Anticholinergic Exposure in Older Adults: the Muscarinic Acetylcholinergic Receptor ANTagonist Exposure Scale
ArticleAbstract: Quantification of the anticholinergic exposure insufficiently or imprecisely incorporates dosage infPalabras claves:Autores:Azermai M., Carlos E. Durán, Christiaens T., Elseviers M., Klamer T., Vander Stichele R., Wauters M.Fuentes:scopusCorrection to: A Landscape Analysis of Post-Marketing Studies Registered in the EU PAS Register and ClinicalTrials.gov Focusing on Pregnancy Outcomes or Breastfeeding Effects: A Contribution from the ConcePTION Project (Drug Safety, (2022), 45, 4, (333-344), 10.1007/s40264-022-01154-7)
OtherAbstract: In the original version of this article, the given and family names of “Leonardo Roque Pereira” werePalabras claves:Autores:Carlos E. Durán, Kontogiorgis C., Lalagkas P.N., Layton D., Pereira L.R., Poulentzas G., Sturkenboom M.C.J.M.Fuentes:scopusEssential medicines in universal health coverage: A scoping review of public health law interventions and how they are measured in five middle-income countries
ArticleAbstract: Very few studies exist of legal interventions (national laws) for essential medicines as part of uniPalabras claves:access to medicines, drug, Essential medicines, health insurance, Health services accessibility, Insurance, Legislation, Middle income country, Pharmaceutical policy, Pharmaceutical services, universal health coverage, Universal health insuranceAutores:Ackon A., Alexandrov N.V., Babar Z.U.D., Brutsaert D., Carlos E. Durán, Demchenko I., El-Dahiyat F., Hafidz F., Haque R., Hussain R., Perehudoff K., Salenga R., Suleman F.Fuentes:scopusEMA and FDA decisions based on flawed evidence to approve new cancer drugs negatively affect Latin American patients
OtherAbstract:Palabras claves:Autores:Cañás M., Carlos E. Durán, Chistiaens T.Fuentes:scopusMyocarditis and pericarditis associated with SARS-CoV-2 vaccines: A population-based descriptive cohort and a nested self-controlled risk interval study using electronic health care data from four European countries
ArticleAbstract: Background: Estimates of the association between COVID-19 vaccines and myo-/pericarditis risk vary wPalabras claves:adverse drug reaction, COVID-19 Vaccine, myocarditis , Pericarditis, pharmacovigilanceAutores:Alsina E., Aragón M., Belitser S.V., Bots S.H., Carlos E. Durán, Douglas I.J., García-Poza P., Gini R., Herings R.M.C., Huerta C., Klungel O.H., Martin I., Martín-Pérez M., Messina D., Overbeek J.A., Pallejà-Millán M., Paoletti O., Riera-Arnau J., Schultze A., Sisay M.M., Souverein P., Sturkenboom M.C.J.M., Swart K.M.A., Villalobos F.Fuentes:scopusImpact of the European Union on access to medicines in low- and middle-income countries: A scoping review
ReviewAbstract: This Scoping Review synthesises evidence of the impacts of European Union (EU) law, regulation, andPalabras claves:Autores:Carlos E. Durán, de Ruijter A., Demchenko I., Mazzanti V., Parwani P., Perehudoff K., Suleman F.Fuentes:scopusPharmaceutical policy in Ecuador
Book PartAbstract: Ecuador has a heterogeneous health system. The 2008 Constitution signaled the start of a process thaPalabras claves:Autores:Carlos E. Durán, Lucio R., Rovira J.Fuentes:scopusSharp rise in the expenditures of targeted drugs in Ecuador: five-year (2010–2014) consumption of oncologic drugs in public and private hospitals
ArticleAbstract: Objective: In Ecuador, a new constitutional mandate (2008) allowed the government to implement freePalabras claves:Cáncer, drug utilization, ECUADOR, health expenditures, Latin America, molecular targeted therapy, oncologic drugsAutores:Carlos E. Durán, Christiaens T., Elseviers M., Rottey S., Vander Stichele R.Fuentes:scopus